Join VisionTech at a very special event: our first ever Member-Guest Live Pitch Event on Tuesday, August 5. Co-hosted by longtime sponsor KSM CPAs + Advisors, the event includes networking and drinks, catered dinner from City Barbecue, and pitches by two portfolio companies, Ateios Systems and Nexosome Oncology, looking for funding to fuel their commercial breakthroughs.
This event is about more than just deal flow. It’s about engaging with bold founders, exchanging ideas, and having fun along the way. VisionTech members are encouraged to bring a guest who’s curious about angel investing and VisionTech—a friend, colleague, or future co-investor. We’ll cover their dinner and drinks.
Meet Pitch Presenter #2: Nexosome Oncology:
Website
Link
Joined VisionTech Portfolio
2021
Fueling Hope with Greatly Improved Early-Stage Cancer Diagnostics
The earlier a person’s cancer is diagnosed, the better the chances are for long-term survival. For example, if breast cancer is diagnosed during stage 1 or 2, the survival rate is 100%. If breast cancer is diagnosed in stage 3 or 4, the five-year survival rate drops to 30% . Likewise, when colon cancer is diagnosed in stage 1 or 2, the survival rate is 91%. That drops to 18% when diagnosed in stage 3 or 4.
Nexosome Oncology is transforming early-stage cancer diagnostics with novel plasma proteomics. Current diagnostic tools have sensitivity rates that range from 3% to 57% for stage 1 cancer. Nexosome Oncology’s sensitivity and specificity rates for stage 1 cancer is greater than 95%.
Technology
Nexosome Oncology’s EV-based proteomics platform enables a complete system-wide view of a cancer’s patient’s biomarkers. The platform looks at three things:
- Tumor-cell specific biomarkers that have a small signal.
- Tumor microenvironment specific biomarkers that have a modest signal.
- Immune response and metabolic changes that have a large signal.
When all of this data is analyzed together, early-stage cancer is nearly 100% detectable, increasing the possibility of successful treatment.
Nexosome Oncology’s technology encompasses a proprietary EV isolation and liquid biopsy, accelerated proteomic biomarker discovery enabled by machine learning, and fast clinical translation into assays attractive to strategic partners for income-generating pilot studies, clinical studies, licensing and sales.
Here Are the Benefits
Ultimately, the most important benefit is creating the opportunity for people to have an earlier diagnosis of life-threatening cancer and greater chances of an extended life.
Commercially, numerous pharmaceutical and diagnostics companies can benefit from using Nexosome Oncology’s platform that looks at all biomarkers rather than just cancer cells to detect the presence of cancer. This has the potential to make current and future cancer detection tools more effective at diagnosing cancer in its earliest, most treatable stages.
About this Round
This is Nexosome Oncology’s Seed Plus Round. The company seeks to raise $2 million on a pre-money valuation of $24 million. They are open to oversubscribing up to $3 million. All VisionTech investors are welcome to participate in this round.
Use of Funds
Nexosome Oncology will use funds from the raise to continue R&D, increasing its IP protection with plans to file for up to six new patents, hire additional staff, and general operations. Additionally, the company has set these goals for 2025-2026:
- Add four new strategic partners
- Achieve strategic sponsored clinical program of $1-3 million
- Secure four to six licensures with royalties over two years
- Generate $2.6 million in profit from these collaborations
- Exit by licensure/acquisition
What Makes this an Attractive Opportunity
The need for earlier diagnostics of cancer is significant. Nexosome Oncology’s technology is a game-changer that can be licensed or acquired by multiple pharmaceutical and diagnostics companies to improve current solutions or develop new approaches. Through paid strategic partnerships, Nexosome Oncology is de-risking the technology, generating come, opening the door to a potential exit, and creating the opportunity for far better cancer diagnostics.
(Close)
Don’t miss the first ever VisionTech Member-Guest Pitch Event on Tuesday, August 5 starting at 5:30 pm at KSM headquarters at 800 East 96th Street, Suite 500 in Indianapolis. The event is all about networking, great food and drinks, and two incredible investment opportunities. FREE to members and guests. Please RSVP no later than Friday, August 1 so we have plenty of ribs, brisket, and sides for everyone. Here’s the link.